Is Flow Cytometric DNA Content Hypodiploidy Prognostic in Multiple Myeloma?

References

• Riley R. S. Cellular proliferation markers in the evaluation of human cancer. Clinics in Laboratory Medicine 1992; 12: 163–199
   PubMed Web of Science ®Google Scholar
• Herman C. J. Cytometic DNA analysis in the management of cancer. Clinical and laboratory considerations. Cancer 1992; 69%(6 Suppl)1553–1556
   PubMed Web of Science ®Google Scholar
• Flint A., Lvoett E. J., Stoolman L. M., McMillan K., Schnitzer B., McClatchey K. D., Hudson J. L. Flow cytometric analysis of DNA in diagnostic cytology. American Journal of Clinical Pathology 1985; 84: 278–282
   PubMed Web of Science ®Google Scholar
• Witzig T. E., Gonchoroff N. J., Therneau T., Gilbertson D. T., Wold L. E., Grant C., Grande J., Katzmann J A., Ahmann D. L., Ingle I. N. DNA content flow cytometry as a prognostic factor for node-postive breast cancer. The role of multiparameter ploidy analysis and specimen sonication. Cancer 1991; 68: 1781–1788
   PubMed Web of Science ®Google Scholar
• Witzig T. E., Loprinzi C. L., Gonchoroff N. J., Reiman H. M., Cha S. S., Wieand H. S., Katzmann J. A., Paulsen J. K., Moertel C. G. A ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 1991; 68: 879–888
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R., Orfao A., Gonzalez M., Moro M. J., Hernandez J. M., Ortega F., Borrego D., Camero M., Casanova F., Jimenez R. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. British Journal of Haematology 1995; 90: 106–112
   PubMed Web of Science ®Google Scholar
• Smith L., Barlogie B., Alexanian R. Biclonal and hypodiploid multiple myeloma. American Journal of Medicine 1986; 80: 841–843
   PubMed Web of Science ®Google Scholar
• Zardecki M., Bernardi F., Lai J. L., Facon T., Izydorczyk V., Bauters F., Cosson A. Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. Cancer Genetics & Cyrogenetics 1994; 74: 115–119
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Palumbo A., Delasalle K. B., Alexanian R. Primary plasma cell leukemia. British Journal of Haematology 1994; 88: 754–759
   PubMed Web of Science ®Google Scholar
• Shimazaki C., Gotoh H., Ashihara E., Oku N., Inaba T., Murakami S., Itoh K., Ura Y., Nakagawa M., Fujita N. Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia. American Journal of Hematology 1992; 39: 159–162
   PubMed Web of Science ®Google Scholar
• Clark R. E., Geddes A. D., Whittaker J. A., Jacobs A. Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma. European Journal of Cancer & Clinical Oncology 1989; 25: 1789–1793
   PubMedGoogle Scholar
• Morgan R. J., Gonchoroff N. J., Katzamnn J. A., Witzig T. E., Kyle R. A., Greipp P. R. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma. American Journal of Hematology 1989; 30: 195–200
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Leong T, Bennett J. M., Gaillard J. P., Klein B., Stewart JA, Kay N. E., Van Ness B., Kyle R. A. Plasmablastic morphology an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) E9487: Report by the ECOG Myeloma Laboratory Group. Blood 1995; 91(7)2501–2507, April 1. 1998.
   Google Scholar
• Kay NE, bong T, Bone N, Kyle RA, Greipp PR, Van Ness B. Oken MM: T-helper phenotypes in the blood of myeloma patients on ECOG phase III mals E 9486/E3A93. British J. Haematology 1998; 100(b)459–463
   PubMed Web of Science ®Google Scholar
• Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O'Fallon WM, Kyle RA. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clinic Proceedings 1987; 62(11)969–977
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Katzmann J. A., Ofallon W. M., Kyle RA. Value of b˜2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219–223
   PubMed Web of Science ®Google Scholar
• Bataille R., Boccadoro M., Klein B., Dune B., Pileri A. C-reactive protein and &-microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–737
   PubMed Web of Science ®Google Scholar
• Trendle M. C., Greipp P. R., Leong T., Oken M. M., Kay N. E., Van Ness B., Kyle R. A. Prognostic significance of the S-phase fraction of light chain restricted cyto-plasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma. Proceeding of the Annual Meeting of the American Society of Clinical Oncology 1996; 15: 1393
   Google Scholar
• Oken M. M., Kyle R. A., Greipp P. R., Kay N. E., Tsiatis A., O'Connell M. J. (1992) Possible survival benefit with chemotherapy plus interferon (rIFN alpha 2) in the treatment of multiple myeloma. ASCO Annual meeting May 17–19. 1992. 1992. San Diego, CA ASCO 11: 1234
   Google Scholar
• Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. British Journal of Haematology 1998; 101(b)189–194, Prognostic value of cytogenetics in multiple myeloma.
   PubMed Web of Science ®Google Scholar
• Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, Grange MJ, Monconduit M, Bastard C. Leukemia 1998; 12(b)960–969, Chromosomal analysis in multiple myeloma; cytogenetic evidence of two different diseases.
   PubMed Web of Science ®Google Scholar
• Calasanz MJ, Cigudosa JC, Odero MD, Garcia-Foncillas J, Marin J, Ardanaz MT, Rocha E, Gullon A. British Journal of Haematology 1997; 98(b)418–425, Hypodiploidy and 22q11 rearrangements at diagnosis an associated with poor prognosis in patients with multiple myeloma.
   PubMed Web of Science ®Google Scholar